Health
Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline
Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead PharmaceuticalsPrecision approach targets patients who have a mutation in the PNPLA3 gene, which is highly prevalent among Hispanic patients with MASHPhase 1 data published in The New England Journal of Medicine demonstrated a 46% liver fat reduction in homozygous patients and a well-tolerated safety profileMadrigal’s pipeline includes more than 10 programs at multiple stages of developme
About this update from Madrigal Pharmaceuticals, Inc.
[{"type":"image","alt":"Madrigal Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Madrigal Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":86,"url":"https://media.zenfs.com/en/globenewswire.com/0a35449b0ee323b8224d49bf845d4cf5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cN2_C_I.OrsxKBO.PLoAhw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMA--/https://media.zenfs.com/en/globenewswire.com/0a35449b0ee323b8224d49bf845d4cf5","width":300,"height":86}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead Pharmaceuticals","length":124,"tagName":"p"}]},{"val":[{"type":"text","content":"Precision approach targets patients who have a mutation in the PNPLA3 gene, which is highly prevalent among Hispanic patients with MASH","length":135,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 1 data published in The New England Journal of Medicine demonstrated a 46% liver fat reduction in homozygous patients and a well-tolerated safety profile","length":159,"tagName":"p"}]},{"val":[{"type":"text","content":"Madrigal’s pipeline includes more than 10 programs at multiple stages of development, anchored by Rezdiffra® (resmetirom) as the foundational treatment","length":151,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":569,"olType":false},{"type":"text","content":"CONSHOHOCKEN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced an exclusive global license agreement with Arrowhead Pharmaceuticals for ARO-PNPLA3, a clinical-stage, small interfering RNA (siRNA) asset targeting patatin-like phospholipase domain-containing protein 3 (PNPLA3), a key genetic driver of MASH.","length":488,"tagName":"p"},{"type":"text","content":"The license of ARO-PNPLA3 adds to Madrigal’s pipeline with a precision medicine approach for patients at high risk of MASH. PNPLA3 I148M, a well-established genetic contributor to MASH progression, is associated with increased liver fat, inflammation, fibrosis, cirrhosis and hepatocellular carcinoma. Approximately 30% of patients with MASH with moderate to adv...